Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study — Fumitaka Suzuki (2021) | RDL Network
Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study
Article 2021 en
Authors
FS
Fumitaka Suzuki
YS
Yoshiyuki Suzuki
YK
Yoshiyasu Karino
Abstract
1 min read
In conclusion, HBsAg reduction was limited after switching from ETV to TDF in this study population. Further investigation is warranted to better understand the clinical impact of switching from ETV to TDF. ClinicalTrials.gov: NCT03258710 registered August 21, 2017. https://clinicaltrials.gov/ct2/show/NCT03258710?term=NCT03258710&draw=2&rank=1.
Discussion(0)
No comments yet. Be the first to comment.